share_log

Beyond The Numbers: 4 Analysts Discuss NovoCure Stock

Benzinga ·  Jul 26 20:01

During the last three months, 4 analysts shared their evaluations of NovoCure (NASDAQ:NVCR), revealing diverse outlooks from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings00400
Last 30D00100
1M Ago00100
2M Ago00100
3M Ago00100

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $24.00 and a low estimate of $20.00. This current average has increased by 6.69% from the previous average price target of $20.62.

1721995310_0.png

Deciphering Analyst Ratings: An In-Depth Analysis

A comprehensive examination of how financial experts...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment